VP, Head of Commercial Operations

Patients with adenoid cystic carcinoma (ACC) have waited decades for a treatment option. At Remix Therapeutics, we intend to change that. We are a clinical-stage biopharmaceutical company that has pioneered a new class of small molecule medicines targeting the RNA splicing machinery — correcting the disease-causing errors that drive ACC and other serious conditions at their source. REM-422 is our lead program, currently in clinical evaluation for ACC and AML/HR-MDS, and it is at a criti